Melatonin for Adolescent Insomnia
For adolescents with delayed sleep-wake phase disorder (DSWPD), start with 0.15 mg/kg (typically 3-5 mg) of fast-release melatonin administered 1.5-2 hours before habitual bedtime, with initial treatment duration of 4-6 weeks.
Dosing Strategy
The American Academy of Sleep Medicine guidelines provide the most robust framework for melatonin use in adolescents 1:
Weight-Based Dosing (Preferred)
- 0.15 mg/kg showed optimal results in controlled trials
- For adolescents without psychiatric comorbidities: typically translates to 3-4 mg
- For adolescents with psychiatric comorbidities (e.g., ADHD): 3 mg if <40 kg; 5 mg if >40 kg 1
Fixed Dosing Alternative
- Start at 3 mg and titrate up by 1 mg every 2 weeks if no response
- Maximum dose: 6 mg 2
- Evidence supports 3-5 mg range as most effective 1
Important caveat: The weight-based approach (0.15 mg/kg) has MODERATE quality evidence, while fixed dosing for psychiatric comorbidities has LOW quality evidence 1.
Timing of Administration
Critical for efficacy: Administer 1.5-2 hours before habitual bedtime 1. This timing is based on:
- Circadian phase-shifting effects requiring administration before endogenous melatonin onset
- Studies showing sleep onset advanced by 36-54 minutes with this timing 1
- Recent meta-analysis suggesting 3 hours before bedtime may be optimal for maximal efficacy 3
Practical approach: If uncertain about optimal timing, start at 1.5-2 hours pre-bedtime per guidelines, but consider advancing to 3 hours if response is suboptimal after 2 weeks.
Duration of Treatment
Initial Trial
- 4-6 weeks for initial assessment of efficacy 1
- Evaluate response at 2 weeks; if no improvement, increase dose by 1 mg 2
Long-Term Use
- Studies demonstrate safety up to 24 months in children with autism 2
- Recommend stopping at least once yearly (preferably during summer) to reassess need 4
- Long-term studies (1-10.8 years) show no substantial developmental concerns 4
Critical consideration: The benefits/harms ratio remains uncertain for long-term use in typically developing adolescents, as rigorous long-term safety data are lacking 1.
Monitoring Plan
Baseline Assessment
- Sleep diary for 1-2 weeks documenting:
- Bedtime and sleep onset time
- Wake time and total sleep time
- Number of night awakenings
- Daytime functioning impact
Follow-Up Schedule
Week 2:
- Assess for adverse effects (morning sleepiness, headache, loose stools)
- Evaluate partial response; consider dose increase if no improvement
Week 4-6:
- Primary efficacy assessment using sleep diary
- Expected improvements: sleep latency reduction of 18-37 minutes 1, 5
- Total sleep time increase of 21-30 minutes 5
Every 3 months (if continuing):
- Reassess ongoing need
- Monitor for adverse effects
- Evaluate daytime functioning and quality of life
Annually:
- Trial discontinuation to assess continued need 4
- Consider developmental assessment if prolonged use (>1 year)
Red Flags Requiring Discontinuation
- Morning sedation affecting school performance
- Paradoxical worsening of sleep
- New behavioral changes
- Any serious adverse events
Safety Considerations
Known Adverse Effects
- Common (non-serious): Morning sleepiness, headache, dizziness, loose stools 1, 2
- Risk ratio for non-serious adverse events: 3.44 compared to placebo 5
- No serious adverse events reported in pediatric trials to date 1, 5
Theoretical Concerns
- Effects on reproductive system development (based on animal studies) 4
- Long-term safety data in typically developing adolescents remain limited 1, 5
- Post-marketing surveillance of ~35 million doses in UK children showed no reported adverse events 4
Informed Consent Requirements
Must discuss with patient and family:
- Limited long-term safety data in typically developing adolescents
- Need for behavioral interventions as first-line treatment
- Importance of sleep hygiene maintenance
- Plan for periodic discontinuation trials
Treatment Algorithm
- First-line: Sleep hygiene education and behavioral interventions
- If inadequate response after 4-6 weeks AND daytime function compromised:
- Start melatonin 0.15 mg/kg (or 3 mg fixed dose)
- Administer 1.5-2 hours before bedtime
- Use fast-release formulation
- Week 2: Assess response and tolerability
- If no improvement: increase by 1 mg
- Week 4-6: Evaluate efficacy
- If effective: continue with quarterly monitoring
- If ineffective at 6 mg: discontinue and reassess diagnosis
- Annually: Trial discontinuation during low-stress period
Never use melatonin as first-line treatment in otherwise healthy adolescents with insomnia 5, 6. The evidence shows benefits are limited and adverse events are likely when behavioral interventions have not been attempted first.